Source:http://linkedlifedata.com/resource/pubmed/id/18685489
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2008-9-29
|
pubmed:abstractText |
Gliomas are the most frequent primary brain tumors. In a minority of cases, the differentiation between astrocytomas and oligodendrogliomas based on morphologic characteristics alone can be difficult; though it is important, as patients with oligodendrogliomas follow a more favorable clinical course. Here we report on the immunohistochemical expression pattern of the oligodendrocytic marker Nogo-A in 113 central nervous system tumors including 28 oligodendrogliomas [15, World Health Organization (WHO) grade II; 13, grade WHO III], 50 astrocytomas [10, grade WHO II; 11, grade WHO III; 29 glioblastoma multiforme (GBM)], 11 ependymomas WHO grade II, 7 central neurocytomas, 2 dysembryoplastic neuroepithelial tumors (DNTs), 5 clear cell meningiomas, and 10 metastases to the brain. The oligodendrocytic marker Nogo-A was found to be strongly expressed in 71% of oligodendrogliomas, but in 0% of ependymomas WHO grade II, astrocytomas WHO grade II or III, DNTs, central neurocytomas, or clear cell meningiomas. In GBM, a subgroup of tumors (24%) showed strong expression of Nogo-A coincidently with Ki67 positivity but glial fibrillary acidic protein-negativity. However, neither in oligodendrogliomas nor GBM was a correlation between the loss of 1p19q and the extent of Nogo-A expression observed. Our findings indicate that Nogo-A is strongly expressed in the majority of oligodendrogliomas and might be a helpful marker to distinguish oligodendrogliomas from astrocytomas WHO grades II and III as well as ependymomas. They also support the hypothesis that GBM may be a heterogeneous group of tumors derived from different progenitor cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1532-0979
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1444-53
|
pubmed:meshHeading |
pubmed-meshheading:18685489-Astrocytoma,
pubmed-meshheading:18685489-Brain Neoplasms,
pubmed-meshheading:18685489-Diagnosis, Differential,
pubmed-meshheading:18685489-Ependymoma,
pubmed-meshheading:18685489-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18685489-Glioblastoma,
pubmed-meshheading:18685489-Glioma,
pubmed-meshheading:18685489-Humans,
pubmed-meshheading:18685489-Immunohistochemistry,
pubmed-meshheading:18685489-Meningioma,
pubmed-meshheading:18685489-Myelin Proteins,
pubmed-meshheading:18685489-Neoplasm Staging,
pubmed-meshheading:18685489-Neurocytoma,
pubmed-meshheading:18685489-Oligodendroglioma,
pubmed-meshheading:18685489-Tumor Markers, Biological
|
pubmed:year |
2008
|
pubmed:articleTitle |
Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
|
pubmed:affiliation |
Institute of Neuropathology, University Hospital Münster, Münster, Germany. tanjakuhlmann@gmx.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|